RNA-Based Drug Discovery and Development for Neurological Conditions
A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuropharmacology and Neuropathology".
Deadline for manuscript submissions: 10 August 2024 | Viewed by 86
Special Issue Editor
Interests: pain mechanisms; cancer pain; neuropathic pain; painful diabetic peripheral neu-ropathy; gene regulation; non-coding RNAs; microRNAs; long non-coding RNAs; genome regulations; RNA therapeutics; itch mechanisms; RNA-therapeutics
Special Issue Information
Dear Colleagues,
Recent breakthroughs have illuminated RNA's pivotal role as a versatile tool in combating a spectrum of challenging neurological disorders. Exciting discoveries in RNA-based biomarkers and novel mechanisms of action have illuminated new paths for therapeutic intervention, heralding a new era of precision medicine. To propel the rapid expansion of the field, there is an urgent need to enhance the efficacy of RNA-based therapeutics and devise innovative modes of delivery. Novel strategies that enable the precise targeting of specific cell types within the complex neural environment are paramount, aiming to maximize therapeutic efficacy while minimizing off-target effects. A comprehensive understanding of the complex interplay within diverse RNA classes in organisms' development and disease is still in its infancy.
Share your insights, innovations, and findings with Brain Sciences, where they will catalyze new discoveries and drive progress in the quest for effective neurological therapies. By submitting your manuscripts, you will not only amplify the impact of your work but also inspire collaboration and cross-disciplinary exchange. Together, let us harness the power of RNA to revolutionize neurological care, offering hope to millions worldwide.
We invite original research articles and reviews that explore the frontiers of RNA-based drug discovery and development, delving into the intricacies of RNA-based biomarkers, novel mechanisms, mode of delivery, and strategies to enhance therapeutic efficacy. Discovery of the vast potential of RNA therapeutics, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), messenger RNA (mRNA) therapeutics, RNA editing technologies, and non-coding RNAs, in the clinical setting as well as with animal models is anticipated.
Dr. Kiran K. Bali
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
- amyotrophic lateral sclerosis (ALS)
- pain
- brain tumors
- brain cavernomas
